BUKWANG PHARMACEUTICAL IND CO.,LTD
Financials
Valuation Metrics
BUKWANG PHARMACEUTICAL IND CO.,LTD's Market Cap is ₩4188B. At end of 2025 it was ₩3734B. Ranked #558 of 2,420 in KR market (top 23%), #330 of 781 on KOSPI (top 42%), #59 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 418.83B KRW | KR#558/2,420 Sec#59/231 |
| Revenue | 215.09B KRW | KR#989/2,420 Sec#55/231 |
| Net Income | 8.70B KRW | KR#1,018/2,420 Sec#63/231 |
| Total Assets | 467.05B KRW | KR#801/2,420 Sec#48/231 |
| Net Assets | 334.39B KRW | KR#678/2,420 Sec#44/231 |
| Employees | 582 | KR#427/2,420 Sec#37/231 |
| Value | ||
| P/E | 48.14x | KR#1,395/2,420 Sec#89/231 |
| P/B | 1.25x | KR#1,595/2,420 Sec#103/231 |
| P/S | 1.95x | KR#1,759/2,420 Sec#102/231 |
| EV/EBITDA | 33.86x | KR#1,216/2,420 Sec#76/231 |
| FCF Yield | 3.39% | KR#946/2,420 Sec#58/231 |
| Profitability | ||
| ROE | 2.60% | KR#1,354/2,420 Sec#93/231 |
| ROA | 1.86% | KR#1,247/2,420 Sec#89/231 |
| Op. Margin | 5.42% | KR#912/2,420 Sec#69/231 |
| Revenue Growth | 20.05% | KR#552/2,420 Sec#52/231 |
| Earnings Growth | -31.88% | KR#992/2,420 Sec#64/231 |
| Financial Health | ||
| Debt Ratio | 39.67% | KR#782/2,420 Sec#91/231 |
| Total Debt | 79.82B KRW | KR#805/2,420 Sec#50/231 |
| FCF | 14.21B KRW | KR#619/2,420 Sec#33/231 |
| Cash | 104.10B KRW | KR#461/2,420 Sec#22/231 |
| Current Ratio | 2.33x | KR#744/2,420 Sec#88/231 |
| Net Debt/EBITDA | -2.08x | KR#227/2,420 Sec#9/231 |
| Dividend | ||
| Div. Yield | 2.93% | KR#625/2,420 Sec#29/231 |
| Performance | ||
| 1Y Return | 16.78% | KR#576/2,420 Sec#34/231 |
| 1M Return | 3.41% | KR#1,163/2,420 Sec#96/231 |
| From 52W High | -57.08% | KR#1,843/2,420 Sec#147/231 |
| 1Y MDD | -61.82% | KR#1,584/2,420 Sec#128/231 |
| Trading | ||
| Volume | 2,464,766 shares | KR#520/2,420 Sec#45/231 |
| Trading Value | 10.81B KRW | KR#817/2,420 Sec#75/231 |
| Foreign Own. | 6.77% | KR#658/2,420 Sec#57/231 |
| Per Share | ||
| EPS | 88 KRW | KR#1,447/2,420 Sec#97/231 |
| BPS | 3,389 KRW | KR#1,782/2,420 Sec#134/231 |
Company Info
Bugwang Pharm, established in 1960 for the purpose of manufacturing and selling pharmaceuticals, was listed on the Securities Market in 1988. The company holds four unlisted subsidiaries, including Denmark-based Contera Pharma A/S, Bugwang Medica Co., Ltd., JaguAHR Therapeutics, and ProteKt Therapeutics. It engages in the manufacturing and sales of pharmaceuticals and quasi-drugs, with major products including Dexid, Ferroba, Legalon, Latuda, and Tasenol. Bugwang Pharm is headquartered in Dongjak-gu, Seoul.